PCV01 is a peptide vaccine harvested from a tumour antigen complex. This is delivered by conjugation with a viral vector platform.
In non-clinical models, the vaccine is immunogenic and prompts an effective immune response against the tumour with a marked delay in tumour growth. It prompts an effective adaptive immune response, including an influx of ‘killer’ T cells; with consequent tumour shrinkage.